The $15.28 million transaction aims to boost medical imaging innovation
Hamilton Locke has acted as the advisor of EMVision Medical Devices Limited on its $15.28 million placement with Keysight Technologies Inc.
The transaction was done to bolster EMVision’s position in the medical imaging technology sector, according to a news release from the law firm.
Specifically, the investment will support the market launch of the emu device, which aims to enhance the diagnosis and treatment of strokes and neurological disorders using portable brain-scanning technology.
Hamilton Locke supported EMVision’s strategic placement through a team headed by partner Jeremy Newman. He was joined by partner Sarah Gilkes, senior associate Janice Yew, and lawyer Brendon Banks.
“This collaboration between EMVision and Keysight Technologies marks a pivotal moment in EMVision’s growth trajectory and highlights the strength of its innovative medical technologies,” said Newman. “We are delighted to have collaborated closely with the team at EMVision throughout the deal process and are proud to have assisted them in achieving this milestone.”
In a separate statement, EMVision CEO & MD Scott Kirkland also referred to the deal as a way to “[support] our vision to revolutionise stroke diagnosis and monitoring in a multi-billion-dollar market and allows us to do so more quickly through expanded trials and data inputs.”
“Keysight is a significant player in the VNA space globally and a highly respected leader in test and measurement solutions,” Kirkland said further. “As such, it is a major endorsement of our technology and innovation to have their backing.”
What are your thoughts on this story? Feel free to comment below.
